Protein A immunoadsorption therapy in HIV-related immune XXXX : a preliminary report.

@entity1 @entity882 @entity1423 @entity11028 @entity794 @entity3440
Nine homosexual @entity1 with immune @entity882 were treated with autologous plasma that had been perfused over @entity3440 -immobilized @entity794 protein A ( @entity11028 ). Pretreatment platelet counts ranged from 10,000 to 98,000 cells/mm3 (mean: 54,000 cells/mm3). Six @entity1 responded to therapy. Platelets increased by a mean of 95,000 cells/mm3 (p less than 0.007) and reached normal levels (greater than 150,000 cells/mm3) in four @entity1 . @entity1423 are presently sustained in these four individuals after 5 months of follow-up. Increases in platelet counts significantly correlated with decreases in platelet-associated IgG (PAIgG), platelet-directed IgG (PDIgG), and immune complexes (CIC). PAIgG and PDIgG declined by a mean of 67% (p less than 0.003) and 58% (p less than 0.007), respectively. CIC decreased by a mean of 37% (p = 0.02). Complement was concomitantly activated in all four examined @entity1 . C3a and C5a increased 23-fold and 2.6-fold, respectively, while total hemolytic complement decreased by 50%. Activated complement components and removal of CIC and IgG thus may contribute to the platelet-enhancing activity of @entity11028 immunoadsorption therapy.
